Cardiogenic shock after 5-fluorouracil administration: a case report and literature review

Abstract Background Cardiogenic shock is a rare adverse event of 5-fluorouracil (5-FU) administration. Because of its rare entity, little is known about epidemiologic and clinical features of 5-FU-induced cardiogenic shock, and recommendations about specific treatment are missing. Case summary We pr...

Full description

Saved in:
Bibliographic Details
Published inEuropean heart journal : case reports Vol. 7; no. 12; p. ytad596
Main Authors Vanoverbeke, Lowie, Wouter, Holvoet, François, D’Heygere, Ivan, Elegeert
Format Journal Article
LanguageEnglish
Published US Oxford University Press 01.12.2023
Subjects
Case Report
Case report
Cardiotoxicity
5-Fluorouracil
Cardiogenic shock
VA-ECMO
Online AccessGet full text

Cover

More Information
Summary:Abstract Background Cardiogenic shock is a rare adverse event of 5-fluorouracil (5-FU) administration. Because of its rare entity, little is known about epidemiologic and clinical features of 5-FU-induced cardiogenic shock, and recommendations about specific treatment are missing. Case summary We present a case of cardiogenic shock and ventricular arrhythmia due to 5-FU-induced toxic cardiomyopathy treated with vasopressor and inotropic drugs in combination with intra-aortic balloon pump. Because of persistent haemodynamic instability, veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and Impella were implanted as a bridge to recovery. Systolic function recovered completely and the patient was weaned successfully. Discussion This case demonstrates toxic cardiomyopathy as a rare and potentially lethal cardiac adverse event of 5-FU administration. This case emphasizes the importance of mechanical support as bridging therapy to recovery of cardiac function.
Bibliography:Conflict of interest: None declared.
ISSN:2514-2119
2514-2119
DOI:10.1093/ehjcr/ytad596